Nektar Therapeutics Reports Q4 Sales Decline to $21.8M, Hurt by Facility Sale and Lower Royalties
Summary
Nektar Therapeutics reported a decline in Q4 revenue to $21.8 million, primarily due to the December 2024 sale of its Huntsville manufacturing facility, which eliminated product sales, and a decrease in non-cash royalty revenue. The company also posted a Q4 EPS of -$1.78 and a net loss of -$36.1 million. While the company recently completed a $460 million public offering to strengthen its financial position and plans to initiate Phase 3 studies for rezpegaldesleukin, the immediate financial results reflect a challenging quarter. Traders will be watching for further updates on the pipeline and how the company manages its financial position post-facility sale.
At the time of this announcement, NKTR was trading at $71.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $6.48 to $75.67. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.